New pill tested for severe transplant complication
NCT ID NCT04941404
First seen Jan 05, 2026 · Last updated Jun 12, 2026 · Updated 19 times
Summary
This study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUCOCORTICOID-REFRACTORY AGVHD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hematology Hospital of the chinese Academy of Medical Sciences
Tianjing, Tianjing, 300020, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215008, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310012, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.